Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists

E. Bremer, B. ten Cate, D.F. Samplonius, N. Mueller, H. Wajant, A.J. Stel, M.E.D. Chamuleau, A.A. van de Loosdrecht, J. Stieglmaier, G.H. Fey, W. Helfrich

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)597-604
JournalCancer Research
Volume68
Issue number2
DOIs
Publication statusPublished - 2008

Cite this

Bremer, E., ten Cate, B., Samplonius, D. F., Mueller, N., Wajant, H., Stel, A. J., ... Helfrich, W. (2008). Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Research, 68(2), 597-604. https://doi.org/10.1158/0008-5472.CAN-07-5171
Bremer, E. ; ten Cate, B. ; Samplonius, D.F. ; Mueller, N. ; Wajant, H. ; Stel, A.J. ; Chamuleau, M.E.D. ; van de Loosdrecht, A.A. ; Stieglmaier, J. ; Fey, G.H. ; Helfrich, W. / Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. In: Cancer Research. 2008 ; Vol. 68, No. 2. pp. 597-604.
@article{1a2ee0327f2e45a292b196203c010372,
title = "Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists",
author = "E. Bremer and {ten Cate}, B. and D.F. Samplonius and N. Mueller and H. Wajant and A.J. Stel and M.E.D. Chamuleau and {van de Loosdrecht}, A.A. and J. Stieglmaier and G.H. Fey and W. Helfrich",
year = "2008",
doi = "10.1158/0008-5472.CAN-07-5171",
language = "Undefined/Unknown",
volume = "68",
pages = "597--604",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

Bremer, E, ten Cate, B, Samplonius, DF, Mueller, N, Wajant, H, Stel, AJ, Chamuleau, MED, van de Loosdrecht, AA, Stieglmaier, J, Fey, GH & Helfrich, W 2008, 'Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists' Cancer Research, vol. 68, no. 2, pp. 597-604. https://doi.org/10.1158/0008-5472.CAN-07-5171

Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. / Bremer, E.; ten Cate, B.; Samplonius, D.F.; Mueller, N.; Wajant, H.; Stel, A.J.; Chamuleau, M.E.D.; van de Loosdrecht, A.A.; Stieglmaier, J.; Fey, G.H.; Helfrich, W.

In: Cancer Research, Vol. 68, No. 2, 2008, p. 597-604.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists

AU - Bremer, E.

AU - ten Cate, B.

AU - Samplonius, D.F.

AU - Mueller, N.

AU - Wajant, H.

AU - Stel, A.J.

AU - Chamuleau, M.E.D.

AU - van de Loosdrecht, A.A.

AU - Stieglmaier, J.

AU - Fey, G.H.

AU - Helfrich, W.

PY - 2008

Y1 - 2008

U2 - 10.1158/0008-5472.CAN-07-5171

DO - 10.1158/0008-5472.CAN-07-5171

M3 - Article

VL - 68

SP - 597

EP - 604

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -